We are very excited to announce this collaboration between Amneal and Metsera to make millions of pens and oral solids of GLP-1 products. This collaboration with Amneal is utterly unique and, for us, incredibly exciting. I've never seen someone put together this kind of technical scale, quality, and affordability commitment- Yeah. with really cutting-edge, you know, new medicines. With Amneal's standard quality track record, over 280 prescription drugs in the market, we are a powerhouse in manufacturing. We are very, very excited on the, breaking the ground on our new facility. It's going to be a high-class, high-quality, state-of-the-art, new technology, new plant. I think it's 2.5 billion worldwide in label for these drugs, and imagine, we could treat half of that. It's about a third of the world population would qualify for one of these drugs. We think healthy weight loss, assisted by therapeutics like those in our pipeline, can be an empowering experience. And I think being able to partner globally in a way that will scale with the demands of that market is really exciting. We are the preferred partner of Metsera to supply this product in U.S. and Europe, and also, Amneal is very excited to get the licensing rights of this product to supply in emerging markets, India, Southeast Asia, Africa. Amneal will bring that capacity. I think we bring the ingenuity of designing the molecules and developing them, and that's gonna make a huge difference to patients. We can effectively play our role to make the humanity better, and that's what drives us.